New Investments, Acquisitions Fostering Growth - Research Report on Teleflex Incorporated, C.R. Bard, Inc., CareFusion Corporation, Wright Medical Group, Inc. and NuVasive, Inc.

Fri Mar 1, 2013 8:04am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130301:nPn2285611


NEW YORK,  March 1, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Teleflex
Incorporated (NYSE: TFX), C.R. Bard, Inc. (NYSE: BCR), CareFusion Corporation
(NYSE: CFN) (NYSE: CFN), Wright Medical Group, Inc. (NASDAQ: WMGI) and NuVasive,
Inc. (NASDAQ: NUVA). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Teleflex Incorporated Research Report

Teleflex recently reported that its fourth quarter revenue rose 4 percent to 
$419 million. Teleflex CEO  Benson Smith  comments that the LMA International
N.V. acquisition greatly contributed to earnings growth. He also said that the
company was able to expand margins and through higher sales volume, new product
introductions and improved pricing. For the coming year, the company's goals
include improving its operating platform, gaining additional market share, and
generating revenue above industry average Teleflex expects to do this by
investing in innovative technologies and prudently investing capital. Morgan
Stanley reiterated its Overweight rating on the company and noted, "Several
underappreciated factors from the quarter leave us more comfortable with our
recent upgrade." The Full Research Report on Teleflex Incorporated - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/c7f9_TFX]

--

C.R. Bard, Inc. Research Report

CR Bard delivered strong fourth quarter results, with diluted EPS of  $1.52  and
 $1.70  on adjusted basis. The company's results exceeded guidance by a couple
of cents. Many are expecting CR Bard to win a vascular graft intellectual
property dispute against privately held Gore soon, and the effects of this may
be reflected as early as the first quarter of 2013. Furthermore, CR Bard's
acquisition of Neomend, a privately owned innovative surgical sealants maker,
may also brighten the company's prospects. To accelerate growth, the company is
presently investing in emerging markets and new product categories. The Full
Research Report on C.R. Bard, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/1101_BCR]

--

CareFusion Corporation (NYSE: CFN) Research Report

CareFusion Corporation reported that its second quarter fiscal 2013 revenue
increased 2 percent to  $909 million, driven by the company's strong Procedural
Solutions segment. It highlighted good performance from its infection prevention
and medical specialties units, which delivered the highest revenue growth in
more than two years. Over the first half of fiscal 2013, the company expanded
operating margins, invested in innovation and new markets. The company's
expansion outside  the United States  through its acquisition of Intermed may
also help further accelerate growth. The Full Research Report on CareFusion
Corporation (NYSE: CFN) - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/03a4_CFN]

--

Wright Medical Group, Inc. Research Report

Wright Medical Group has impressed many analysts and investors with its fourth
quarter and full year results. For 2012, the company was able to implement
transformational changes like leveraging its direct sales organization,
introducing new products, driving productivity gains and increasing its medical
education programs. These changes are reflected in the growth of its foot and
ankle business. Following its results, Leerink Swann upgraded the company from
"market perform" to "outperform." Analysts at Wunderlich also raised their price
target on the shares of Wright Medical. Its recent merger with BioMetric
Therapeutics further brightens the company's outlook, accelerating growth in
Wright's extremities business. With The Full Research Report on Wright Medical
Group, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/78f1_WMGI]

--

NuVasive, Inc. Research Report

NuVasive closed 2012 with strong results, reporting 15 percent growth in revenue
for the full year. Moving forward, the company is excited about its growing
clinical evidence business, new products and expansion to international markets.
NuVasive's most recent expansion move is offering eXTreme Lateral Interbody
Fusion (XLIF) in  Japan. The company is eager to further introduce the product
in  Japan  and drive the shift toward minimally invasive approaches in the
world's second largest spine market. Its long-term plans include evolving into a
 $1 billion  company with steadily increasing profitability. By accelerating its
speed of innovation and expanding to lucrative markets, NuVasive may be on track
towards this goal. The Full Research Report on NuVasive, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to download
free of charge at:
[http://www.investors-alliance.com/r/full_research_report/463c_NUVA]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@Investors-Alliance.com

Main: +1-480-745-7826


SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.